Raising R&D Funds Through a Stock Listing and Public Offering
First written in FY2021. 3 of 7 entries say "Restated". Latest entry: FY2025.
1 other company's latest entry also says "Restated".
- FY2025RestatedAnnual report
「The proceeds raised through the public offering at the time of the June 2021 stock listing are being used primarily for research and development expenses for existing pipelines, as well as for the research and development and introduction of new pipelines.」
The company has reaffirmed its policy of using the proceeds from the public offering at the time of the listing for research and development and other purposes related to its existing and new pipelines. - FY2024-Q1Change in Use of ProceedsAnnual report
「The initial plan included ¥396.198 million to be raised through an over-allotment. However, as no over-allotment was conducted and the proceeds after deducting fees and other expenses amounted to ¥2,622.544 million, the allocation of the proceeds was revised.」
The use of the funds raised at the time of the listing was revised to reflect the actual proceeds. While the planned allocation to the PV trial was reduced because of difficulties enrolling PV patients, allocations to the development costs of PPMX-T002 and PPMX-T004, capital investment to improve antibody technology, and the recruitment of researchers were increased. - FY2023RestatedAnnual report
「The proceeds raised through the public offering at the time of the June 2021 stock listing are intended primarily for research and development expenses for existing pipelines, as well as for the research and development and introduction of new pipelines.」
The company has reaffirmed its policy of using the proceeds from the public offering at the time of the listing for research and development and other purposes related to its existing and new pipelines. - FY2022RestatedAnnual report
「Cash flows from financing activities amounted to proceeds of ¥2,647.548 million, compared with ¥1,011.040 million in the previous fiscal year. The main factors were ¥2,623.975 million in proceeds from the public offering conducted in connection with the listing of the company's shares on the Tokyo Stock Exchange Mothers market and ¥28.440 million in proceeds from the issuance of shares upon the exercise of share acquisition rights, among other items.」
The proceeds raised through the public offering at the time of the listing and the exercise of share acquisition rights have been confirmed on an annual basis. - FY2022-Q2AdvancedAnnual report
「The main factors were ¥2,623.975 million in proceeds from the public offering conducted in connection with the listing of the company's shares on the Tokyo Stock Exchange Mothers market and ¥28.440 million in proceeds from the exercise of share acquisition rights.」
In addition to the proceeds from the public offering, ¥28.440 million was raised through the exercise of share acquisition rights, bringing proceeds from financing activities to ¥2,647.548 million. - FY2022-Q1AdvancedAnnual report
「Cash and deposits of ¥2,641.320 million raised through a public offering in connection with the listing of the company's shares on the Tokyo Stock Exchange Mothers market」
The listing on the Tokyo Stock Exchange Mothers market on 22 June 2021 and the raising of ¥2,641.320 million through a public offering of 3,300,000 shares were completed, increasing share capital and the capital reserve by ¥1,320.660 million each. - FY2021First statedAnnual report
「The issuance of 3,300,000 new shares through a paid-in public offering, with a payment date of 21 June 2021, increased share capital and the capital reserve by ¥1,320.660 million each. The issue price was ¥870 and the underwriting price was ¥800.40.」
The company conducted a public offering in connection with its June 2021 listing on the TSE Mothers market and indicated that the proceeds would be used to fund research and development for its existing and new pipelines.